British drugmaker AstraZeneca (LSE: AZN) has reported positive high-level results from the Phase III HIMALAYA trial, testing a combination of in-house checkpoint blockers.
The firm is evaluating the impact of a single, high priming dose of its novel CTLA-4 targeting antibody tremelimumab, followed by Imfinzi (durvalumab), in the first-line treatment of liver cancer.
Despite previous mixed results from its development program, interest in tremelimumab was revived earlier in 2021, with data from the POSEIDON trial suggesting it could be used to boost efficacy in the highly significant front-line non-small cell lung cancer (NSCLC) setting.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze